Telangiectatic osteogenic sarcoma. Improved survival with combination chemotherapy

Area of Science:

• Oncology
• Orthopedic Oncology
• Chemotherapy

Background:

• Telangiectatic osteogenic sarcoma (TOS) is a rare subtype of osteogenic sarcoma (OS).
• Historically, TOS has been associated with a poor prognosis.
• Adjuvant chemotherapy has become a standard treatment for OS.

Purpose of the Study:

• To evaluate the efficacy of adjuvant chemotherapy regimens in patients with pure telangiectatic osteogenic sarcoma.
• To assess the long-term outcomes and survival rates for TOS patients treated with different chemotherapy protocols.

Main Methods:

• Retrospective analysis of 25 patients with pure TOS treated between 1973 and 1980.
• Patients received surgery (amputation or resection) followed by distinct adjuvant chemotherapy protocols (T-4, T-7, T-10).
• Protocols included high-dose methotrexate with citrovorum factor rescue (HDMTX-CFR), Adriamycin (ADR), cyclophosphamide (CYC), and other agents like bleomycin, dactinomycin, and cisplatinum.

Main Results:

• 17 out of 25 patients (68%) remained disease-free at a mean follow-up of over 5.5 years.
• Disease-free survival rates varied by protocol: 5/10 on T-4, 6/9 on T-7, and 6/6 on T-10.
• Two treatment-related deaths occurred due to HDMTX toxicity in earlier treatments.

Conclusions:

• Telangiectatic osteogenic sarcoma is responsive to adjuvant chemotherapy.
• The findings suggest that TOS is potentially curable with a combination of chemotherapy and surgery.
• These results challenge previous notions of a uniformly poor prognosis for TOS.